Jason P. Steik

Chief Clinical OfficeratPennant Group· In proxies 2021–2025

Pay in FY2025+81% from the year before · Pennant Group stock +6.1% the same year

Jason P. Steik was paid $1.8M in FY2025 (Dec), up 81%. Pennant Group stock rose 6.1% that year.

Pay$100 in the stock at the end of FY20 → $48

Pay is from the Summary Compensation Table of each Pennant Group proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

PNTG
Pennant GroupPublic company · 5 yr
- Chief Clinical Officer2021 – Present · 5 yrStock in role -31%

Roles come from the proxy statements of each company.

Activity

Pay
Pennant Group Chief Clinical Officer pay rose 81% to $1.8M. The stock rose 6% in FY2025 (Dec).
DEF 14AMar 31, 2026
Pay
Pennant Group Chief Clinical Officer pay rose 40% to $1.0M. The stock rose 91% in FY2024 (Dec).
DEF 14AApr 17, 2025
Pay
Pennant Group Chief Clinical Officer pay rose 39% to $721.0K. The stock rose 27% in FY2023 (Dec).
DEF 14AApr 11, 2024
Pay
Pennant Group Chief Clinical Officer pay rose 42% to $520.2K. The stock fell 52% in FY2022 (Dec).
DEF 14AApr 11, 2024

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?